Arrested protein synthesis increases persister-like cell formation

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1468-1473

  Kwan, Brian W ^a   Valenta, John A ^c   Benedik, Michael J ^c   Wood, Thomas K ^a,b  

^a The Pennsylvania State University   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; CIPROFLOXACIN; RIFAMPICIN; TETRACYCLINE;

ARTICLE; BACTERIAL STRAIN; CELL KILLING; CELL TYPE; DRUG DNA BINDING; ESCHERICHIA COLI; NONHUMAN; PERSISTER CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

ADAPTATION, PHYSIOLOGICAL; ADENOSINE TRIPHOSPHATE; BIOFILMS; CARBONYL CYANIDE M-CHLOROPHENYL HYDRAZONE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; MICROBIAL SENSITIVITY TESTS; NUCLEIC ACID SYNTHESIS INHIBITORS; PROTEIN BIOSYNTHESIS; PROTEIN SYNTHESIS INHIBITORS; PROTON IONOPHORES; RIFAMPIN; TETRACYCLINE; TRANSCRIPTION, GENETIC;

EID: 84874049477     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02135-12     Document Type: Article

References (48)

1. Bigger JW. 1944. Treatment of staphylococcal infections with penicillin by intermittent sterilisation. Lancet 244:497-500.
2. Wiuff C, Zappala RM, Regoes RR, Garner KN, Baquero F, Levin BR. 2005. Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrob. Agents Chemother. 49:1483- 1494.
3. Lewis K. 2007. Persister cells, dormancy, and infectious disease. Nat. Rev. Microbiol. 5:48 -56.
4. Lewis K. 2008. Multidrug tolerance of biofilms and persister cells. Curr. Top. Microbiol. Immunol. 322:107-131.
5. Hall-Stoodley L, Costerton JW, Stoodley P. 2004. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2:95-108.
6. Wolcott R, Dowd S. 2011. The role of biofilms: are we hitting the right target? Plast. Reconstr. Surg. 127:28S-35S.
7. Jayaraman R. 2008. Bacterial persistence: some new insights into an old phenomenon. J. Biosci. 33:795- 805.
8. Spoering AL, Lewis K. 2001. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J. Bacteriol. 183:6746-6751.
9. Lewis K. 2000. Programmed death in bacteria. Microbiol. Mol. Biol. Rev. 64:503-514.
10. Tan Q, Awano N, Inouye M. 2011. YeeV is an Escherichia coli toxin that inhibits cell division by targeting the cytoskeleton proteins, FtsZ and MreB. Mol. Microbiol. 79:109 -118.
11. Wang X, Wood TK. 2011. Toxin-antitoxin systems influence biofilm and persister cell formation and the general stress response. Appl. Environ. Microbiol. 77:5577-5583.
12. Lewis K. 2010. Persister cells. Annu. Rev. Microbiol. 64:357-372.
13. Ren D, Bedzyk LA, Thomas SM, Ye RW, Wood TK. 2004. Gene expression in Escherichia coli biofilms. Appl. Microbiol. Biotechnol. 64: 515-524.
14. González Barrios AF, Zuo R, Hashimoto Y, Yang L, Bentley WE, Wood TK. 2006. Autoinducer 2 controls biofilm formation in Escherichia coli through a novel motility quorum-sensing regulator (MqsR, B3022). J. Bacteriol. 188:305-316.
15. Wang X, Kim Y, Hong SH, Ma Q, Brown BL, Pu M, Tarone AM, Benedik MJ, Peti W, Page R, Wood TK. 2011. Antitoxin MqsA helps mediate the bacterial general stress response. Nat. Chem. Biol. 7:359 -366.
16. Wang X, Lord DM, Cheng H-Y, Osbourne DO, Hong SH, Sanchez-Torres V, Quiroga C, Zheng K, Herrmann T, Peti W, Benedik MJ, Page R, Wood TK. 2012. A new type V toxin-antitoxin system wheremRNAfor toxin GhoT is cleaved by antitoxin GhoS. Nat. Chem. Biol. 8:855- 861.
17. Brown BL, Wood TK, Peti W, Page R. 2011. Structure of the Escherichia coli antitoxin MqsA (YgiT/b3021) bound to its gene promoter reveals extensive domain rearrangements and the specificity of transcriptional regulation. J. Biol. Chem. 286:2285-2296.
18. Brown BL, Grigoriu S, Kim Y, Arruda JM, Davenport A, Wood TK, Peti W, Page R. 2009. Three dimensional structure of the MqsR:MqsA complex: a novel TA pair comprised of a toxin homologous to RelE and an antitoxin with unique properties. PLoS Pathog. 5:e1000706. doi:10.1371/journal.ppat.1000706.
19. Kim Y, Wang X, Zhang X-S, Grigoriu S, Page R, Peti W, Wood TK. 2010. Escherichia coli toxin/antitoxin pair MqsR/MqsA regulate toxin CspD. Environ. Microbiol. 12:1105-1121.
20. Shah D, Zhang Z, Khodursky AB, Kaldalu N, Kurg K, Lewis K. 2006. Persisters: a distinct physiological state of E. coli. BMC Microbiol. 6:53.
21. Kim Y, Wood TK. 2010. Toxins Hha and CspD and small RNA regulator Hfq are involved in persister cell formation through MqsR in Escherichia coli. Biochem. Biophys. Res. Commun. 391:209 -213.
22. Hong SH, Wang X, O'Connor HF, Benedik MJ, Wood TK. 2012. Bacterial persistence increases as environmental fitness decreases. Microb. Biotechnol. 5:509 -522.
23. Yamaguchi Y, Park J-H, Inouye M. 2009. MqsR, a crucial regulator for quorum sensing and biofilm formation, is a GCU-specific mRNA interferase in Escherichia coli. J. Biol. Chem. 284:28746 -28753.
24. Dörr T, Vulić M, Lewis K. 2010. Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol. 8:e1000317. doi: 10.1371/journal.pbio.1000317.
25. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. 2004. Bacterial persistence as a phenotypic switch. Science 305:1622-1625.
26. Allison KR, Brynildsen MP, Collins JJ. 2011. Heterogeneous bacterial persisters and engineering approaches to eliminate them. Curr. Opin. Microbiol. 14:1- 6.
27. Dörr T, Lewis K, Vulić M. 2009. SOS response induces persistence to fluoroquinolones in Escherichia coli. PLoS Genet. 5:e1000760. doi:10.1371/journal.pgen.1000760.
28. Wehrli W, Knüsel F, Schmid K, Staehelin M. 1968. Interaction of rifamycin with bacterial RNA polymerase. Proc. Natl. Acad. Sci. U.S.A. 61:667- 673.
29. Chopra I, Roberts M. 2001. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65:232-260.
30. Cavari BZ, Avi-Dor Y, Grossowicz N. 1967. Effect of carbonyl cyanide m-chlorophenylhydrazone on respiration and respiration-dependent phosphorylation in Escherichia coli. Biochem. J. 103:601- 608.
31. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
32. Donegan K, Matyac C, Seidler R, Porteous A. 1991. Evaluation of methods for sampling, recovery, and enumeration of bacteria applied to the phylloplane. Appl. Environ. Microbiol. 57:51-56.
33. Sanders CC. 1988. Ciprofloxacin: in vitro activity, mechanism of action, and resistance. Rev. Infect. Dis. 10:516 -527.
34. Fisher JF, Meroueh SO, Mobashery S. 2005. Bacterial resistance to -lactam antibiotics: compelling opportunism, compelling opportunity. Chem. Rev. 105:395- 424.
35. Tuomanen E, Cozens R, Tosch W, Zak O, Tomasz A. 1986. The rate of killing of Escherichia coli by -lactam antibiotics is strictly proportional to the rate of bacterial growth. J. Gen. Microbiol. 132:1297-1304.
36. Wehrli W. 1983. Rifampin: mechanisms of action and resistance. Rev. Infect. Dis. 5:S407-S411.
37. Calvori C, Frontali L, Leoni L, Tecce G. 1965. Effect of rifamycin on protein synthesis. Nature 207:417- 418.
38. Stubbings W, Bostock J, Ingham E, Chopra I. 2006. Mechanisms of the post-antibiotic effects induced by rifampicin and gentamicin in Escherichia coli. J. Antimicrob. Chemother. 58:444-448.
39. Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. 2004. Persister cells and tolerance to antimicrobials. FEMS Microbiol. Lett. 230:13-18.
40. Athamna A, Athamna M, Medlej B, Bast DJ, Rubinstein E. 2004. In vitro post-antibiotic effect of fluoroquinolones, macrolides, -lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis. J. Antimicrob. Chemother. 53:609-615.
41. Gal K. 1965. Combined antibiotic therapy. Can. Med. Assoc. J. 93: 844 - 847.
42. Forrest GN, Tamura K. 2010. Rifampin combination therapy for nonmycobacterial infections. Clin. Microbiol. Rev. 23:14 -34.
43. Roberts MC. 2003. Tetracycline therapy: update. Clin. Infect. Dis. 36: 462-467.
44. Maisonneuve E, Shakespeare LJ, Jørgensen MG, Gerdes K. 2011. Bacterial persistence by RNA endonucleases. Proc. Natl. Acad. Sci. U.S.A. 108:13206 -13211.
45. Kint CI, Verstraeten N, Fauvart M, Michiels J. 2012. New-found fundamentals of bacterial persistence. Trends Microbiol. 20:577-585.
46. Vega NM, Allison KR, Khalil AS, Collins JJ. 2012. Signaling-mediated bacterial persister formation. Nat. Chem. Biol. 8:431- 433.
47. Fajardo A, Martínez JL. 2008. Antibiotics as signals that trigger specific bacterial responses. Curr. Opin. Microbiol. 11:161-167.
48. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. 2006. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2:2006.0008. doi:10.1038/msb4100050.